792OA randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC). (23rd October 2018) - Chi, K N; Taavitsainen, S; Iqbal, N; Ferrario, C; Ong, M; Wadhwa, D; Hotte, S J; Lo, G; Tran, B; Azad, A; Wood, L; Gingerich, J R; et al.